New hope for tough bone cancers: experimental drug trial opens
NCT ID NCT07144254
Summary
This early-stage study is testing a new drug called tegavivint, combined with an existing chemotherapy (gemcitabine), for people whose osteosarcoma (a type of bone cancer) has come back or stopped responding to standard treatments. The main goal is to find the safest and most effective dose of this combination. The trial is open to children and adults who meet specific health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Arthur M. Blank Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.